3-(3-硝基苯基)-3-氧代丙酸甲酯 | 83256-99-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-(3-硝基苯基)-3-氧代丙酸甲酯
• 英文名称: methyl 3-(3-nitrophenyl)-3-oxopropanoate
• CAS: 83256-99-9
• 化学式: C₁₀H₉NO₅
• 分子量: 223.185
• InChiKey: DEDHBEWHJGEANM-UHFFFAOYSA-N

物化性质

• 熔点：
  115-116 °C(Solv: ethanol (64-17-5); water (7732-18-5))
• 沸点：
  298.9±15.0 °C(Predicted)
• 密度：
  1.318±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  89.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(3-硝基苯基)-3-氧代丙酸甲酯 在 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 18.0h， 生成 7-methyl-4-(3-nitrophenyl)-8-(trifluoromethyl)-1H-benzo[b][1,4]diazepin-2(3H)-one
  参考文献：
  名称：

  [EN] METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF
  [FR] MODULATEURS ALLOSTÉRIQUES NÉGATIFS (NAM) DU RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE ET UTILISATIONS DE CEUX-CI

  摘要：

  本文提供了小分子活性代谢型谷氨酸亚型-2和-3受体负向变构调节剂（NAMs），包括这些化合物的组合物，以及使用这些化合物和组合物的方法。

  公开号：

  WO2015191630A1
• 作为产物：
  描述：

  在 sodium hydride 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 3-(3-硝基苯基)-3-氧代丙酸甲酯
  参考文献：
  名称：

  Synthesis of .beta.-Dicarbonyl Compounds via the Conjugate Addition of Benzaldoximate Anion to .alpha.,.beta.-Acetylenic Carbonyl Compounds

  摘要：

  DOI：

  10.1021/jo00084a051

文献信息

• Substituted bicyclic compounds as farnesoid X receptor modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11254663B2

  公开（公告）日：2022-02-22

  Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  公开的是式 (I) 化合物： 或其立体异构体、同系物、盐或溶液，其中所有变量如本文所定义。这些化合物可调节法尼类固醇 X 受体（FXR）的活性，例如作为激动剂。还公开了包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与 FXR 失调相关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性紊乱。
• WO2020168143A5
  申请人：——

  公开号：WO2020168143A5

  公开（公告）日：2022-12-22
• WO2020168148A5
  申请人：——

  公开号：WO2020168148A5

  公开（公告）日：2022-12-20
• The preparation of polymer bound β-ketoesters and their conversion into an array of oxazoles
  作者：Bruce Clapham、Sang-Hyeup Lee、Guido Koch、Jürg Zimmermann、Kim D. Janda

  DOI：10.1016/s0040-4039(02)01076-6

  日期：2002.7

  A series of diverse polymer bound beta-ketoesters have been prepared using a transesterification reaction between t-butyl beta-ketoesters and a hydroxybutyl functionalized JandaJel resin. Additionally, these highly useful polymer bound substrates have also been prepared using a transesterification reaction with commercially available methyl or ethyl beta-ketoesters using lithium perchlorate as a catalyst. The polymer bound beta-ketoesters were then converted into the corresponding alpha-diazo-beta-ketoesters using standard diazo transfer conditions and these products were utilized in the synthesis of an array of oxazoles. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Structure–activity studies of a series of dipyrazolo[3,4- b :3′,4′- d ]pyridin-3-ones binding to the immune regulatory protein B7.1
  作者：Neal J. Green、Jason Xiang、Jing Chen、Lihren Chen、Audrey M. Davies、Dave Erbe、Steve Tam、James F. Tobin

  DOI：10.1016/s0968-0896(03)00183-4

  日期：2003.7

  The interaction of co-stimulatory molecules on T cells with 137 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases. To this end, specific small molecule inhibitors of human B7.1 were identified and characterized. Herein, we report the identification of potent small molecule inhibitors of the B7.1-CD28 interaction. In a high-throughput screen we identified several leads that prevented the interaction of B7.1 with CD28 with activities in the nanomolar to low micromolar range. One of these, the dihydrodipyrazolopyridinone 1, was subsequently shown to bind the V-like domain of human B7.1 at equimolar stoichiometry. With this as a starting point, we report here the synthesis and initial in vitro structure-activity relationships of a series of these compounds. (C) 2003 Elsevier Science Ltd. All rights reserved.